Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NOPHO-DBH AML 2012 Protocol Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years NOPHO-DBH AML protocol. Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years

Trial Profile

NOPHO-DBH AML 2012 Protocol Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years NOPHO-DBH AML protocol. Research study for treatment of children and adolescents with acute myeloid leukaemia 0-18 years

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jul 2019

At a glance

  • Drugs Daunorubicin (Primary) ; Fludarabine (Primary) ; Cytarabine; Etoposide; Mitoxantrone
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms AML 2012; NOPHO-DBH AML 2012
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 Apr 2013 New source identified and integrated: ClinicalTrials.gov record.
    • 23 Feb 2013 Additional lead trial centres identified as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top